Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cortexyme Inc (CRTX)

Cortexyme Inc (CRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,947,038
  • Shares Outstanding, K 26,852
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,480 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.39
  • Number of Estimates 1
  • High Estimate -0.39
  • Low Estimate -0.39
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.18 +60.49%
on 02/05/20
73.84 -1.80%
on 02/14/20
+21.10 (+41.04%)
since 01/14/20
3-Month
23.00 +215.26%
on 11/18/19
73.84 -1.80%
on 02/14/20
+49.42 (+214.03%)
since 11/14/19

Most Recent Stories

More News
Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer's Disease

Cortexyme, Inc. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company's lead investigational medicine in development for mild to moderate Alzheimer's disease...

CRTX : 72.51 (+13.12%)
Cortexyme Announces Closing of $125 Million Private Placement

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases, today announced...

JMP : 3.04 (+0.33%)
CRTX : 72.51 (+13.12%)
Cortexyme Announces $125 Million Private Placement

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases, today announced...

CRTX : 72.51 (+13.12%)
Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company's Lead Investigational Medicine

-- Lysine-gingipains from P. gulae were found in the neurons of aged dogs, paralleling the discovery of gingipains from P. gingivalis in Alzheimer's brains

CRTX : 72.51 (+13.12%)
Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer's Disease

--- GAIN Trial to continue as planned following pre-specified DMC safety data review

CRTX : 72.51 (+13.12%)
Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer's...

CRTX : 72.51 (+13.12%)
The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

BABA : 219.63 (-0.33%)
CRTX : 72.51 (+13.12%)
BYND : 116.22 (+3.76%)
RVLV : 19.49 (+2.74%)
UBER : 39.66 (-1.07%)
5 Hottest IPOs of 2019

2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.

BABA : 219.63 (-0.33%)
CRTX : 72.51 (+13.12%)
RVLV : 19.49 (+2.74%)
LYFT : 44.69 (-4.98%)
BYND : 116.22 (+3.76%)
UBER : 39.66 (-1.07%)
Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer's Disease

Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the "gingipain hypothesis" for Alzheimer's...

CRTX : 72.51 (+13.12%)
Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer's...

CRTX : 72.51 (+13.12%)
Trade CRTX with:

Business Summary

Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The company's drug candidate consists of COR388 which is in clinical stage. Cortexyme Inc. is based in San Francisco, United States....

See More

Key Turning Points

2nd Resistance Point 80.22
1st Resistance Point 76.36
Last Price 72.51
1st Support Level 66.13
2nd Support Level 59.75

See More

52-Week High 73.84
Last Price 72.51
Fibonacci 61.8% 53.02
Fibonacci 50% 46.59
Fibonacci 38.2% 40.17
52-Week Low 19.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar